Ab cellera stock bot
AbCellera Biologics (ABCL) has a bullish consensus rating with a median price target of $9.50, ranging from $7.00 to $12.00, based on the analysis of 13 Wall Street analysts. The overall analyst rating is a Strong Buy (9.3/10), implying a potential upside of 189.6% from its current trading price of $3.28. This outlook is supported by 7 Buy, 1 Hold, and 0 Sell ratings.